Antigen-antibody immunogenic complex: Promising novel vaccines for microbial persistent infections

Expert Opinion on Biological Therapy

Volumn 9, Issue 3, 2009, Pages 285-291

  Wen, Yu Mei ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Antigen antibody immunogenic complex; Clinical trials; Dendritic cells; Hepatitis B virus; Persistent infection; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTIINFECTIVE AGENT; CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIB; GAMMA INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 2; PLASMID DNA; VIRUS DNA; BACTERIAL VACCINE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUCK; ERYTHEMA; GENE MUTATION; GENETIC RECOMBINATION; HEPATITIS B; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PAIN; PROMOTER REGION; REVIEW; SEROCONVERSION; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VACCINE PRODUCTION; VIRUS LOAD; VIRUS MUTANT; ANIMAL; BACTERIAL INFECTION; IMMUNOLOGY; IMMUNOTHERAPY;

HEPATITIS B VIRUS; MUS MUSCULUS;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; BACTERIAL INFECTIONS; BACTERIAL VACCINES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY;

EID: 65549145582     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802715749     Document Type: Review

References (31)

1. Terres G, Wolins W. Enhanced immunological sensitization of mice by the simultaneous injection of antigen and specific antiserum. I. Effect of varying the amount of antigen used relative to the antiserum. J Immunol 1961;86:361-368
2. Randall RE, Young DF, Southern JA. Immunization with solid matrix-antibody-antigen complexes containing surface or internal virus structural proteins protect mice from infection with the paramyxovirus, simian virus 5. J Gen Virol 1988;69:2517-2526 (Pubitemid 18242719)
3. Randall RE, Young DF. Solid matrix-antibody-antigen complexes induce specific CD8+ cells that clear a persistent paramyxovirus infection. J Virol 1991;65:719-726
4. Berzofsky JA, Bensussan A, Cease KB, et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988;334:706-708 (Pubitemid 18197569)
5. Nydegger UE. Immune-complex pathophysiology. Ann NY Acad Sci 2007;1109:66-83
6. Devey ME, Bleasdale K, Stanley C, Steward MW. Failure of affinity maturation leads to increased susceptibility to immune complex glomeruolonephritis. Immunology 1984;52:377-383 (Pubitemid 14109574)
7. Wang WK, Chen HL, Yang CF, et al. Slower rates of clearance of viral load and virus-containing immune complexes in patients with dengue hemorrhagic fever. Clin Infect Dis 2006;43:1023-1030 (Pubitemid 44631103)
8. Celis E, Zurawski VR, Chang TW. Regulation of T cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies. Proc Natl Acad Sci USA 1984;81:6846-6850 (Pubitemid 15221018)
9. Xiong SD, Zhang W, Wen YM. Establishment and verification of an animal model of immunological tolerance against hepatitis B virus. Acta Academiae Medicinae Shanghai 1993;20:321-326
10. Wen YM, Zhang W, Xu YY, et al. Elimination of immune tolerance to hepatitis B in an animal model. Chin Med J 2002;105:199-203
11. Wen YM, Xiong SD, Zhang W. Solid matrix-antibody-antigen complex can clear viremia and antigenemia in persistent duck hepatitis B virus infection. J Gen Virol 1994;78:335-339 (Pubitemid 24050391)
12. Wen YM, Qu D, Zhou SH. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 1999;15:251-258 (Pubitemid 29263243)
13. Zhou SH, Qu D, Wen YM, et al. Studies on HBsAg-anti-HBs complex inducing humoral immune responses. Chin J Microbiol Immunol 1998;18:331-335
14. Zheng BJ, Ng MH, He LF, et al. Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice. Vaccine 2001;19:4219-4225 (Pubitemid 32703643)
15. Zheng BJ, Zhou J, Qu D, et al. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004;11:217-224 (Pubitemid 38658446)
16. Sodomann CP, Schmidt R, Martini GA. Circulating immune complexes (CIC) in acute and chronic viral hepatitis and their sequelae. In: Szmuness W, Alter HJ, Maynard JE, ediors, Viral hepatitis. The Franklin Institute Press, 1982. p. 791-792
17. Zhang JM, Xu Y, Wang XY, et al. Coexistence of hepatitis B surface antigen and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Inf Dis 2007;44:1161-1169 (Pubitemid 46651239)
18. Wen Y, He L, Qu D. Composite vaccine which contains antigen, antibody and recombinant DNA and its preparing method. US6221664; 2001
19. European patent 913157
20. Xu DZ, Huang KL, Zhao K, et al. Vaccination with recombinant HBsAg-HBIG complex in healthy adults. Vaccine 2005;23:2658-2664 (Pubitemid 40385099)
21. Yao X, Zheng BJ, Zhou J, et al. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine 2007;25:1771-1779 (Pubitemid 46188371)
22. Xu DZ, Zhao K, Guo LM, et al. A randomized controlled Phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. Plos One 2008;3:e2565. Published online 2 July 2008, doi:10.1371/journal.pone.0002565
23. Ma ZM, Tian XC, Li XX, et al. Studies on hepatitis B S gene mutation in chronic hepatitis B patients treated with HBsAg-HBIG immunogenic complex therapeutic vaccine. J Microbes Infect (Chinese) 2007;2:68-72
24. Schuurhuis DH, Van Montfoort N, Ioan-Facsinay A, et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol 2006;176:4573-4580
25. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, et al. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol 2002;168:2240-2246 (Pubitemid 34171824)
26. Wen YM, Yuan ZH, Yao X. Experimental and clinical studies on hepatitis B surface antigen-antibody complex therapeutic vaccine. In: Denyer DV, editor, Progress in Hepatitis B Research. Nova Science Publishers, Inc., New York, 2007. p. 203-216
27. Yuen MF, Hui CK, Wu CH, et al. Long term follow-up of interferon-α treatment in Chinese patients with chronic hepatitis B infection. The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001;34:139-145
28. Akbar SMF, Furukawa S, Onji M, et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004;29:136-141 (Pubitemid 38780128)
29. Huang X, Liu L, Ren L, et al. Mucosal priming with replicative Tiantan vaccinia and systemic boosting with DNA vaccine raised strong mucosal and systemic HIV-specific immune responses. Vaccine 2007;52:874-884 (Pubitemid 350192050)
30. Nimmerjahn F, Rovetch J. Fcγ receptors as regulators of immune responses. Nature Reviews Immunology 2008;8:34-47
31. Barabas AZ, Cole CD, Barabas AD, Lafreniere R. A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann NY Acad Sci 2007;1110:619-629 (Pubitemid 350043051)